Hepatic Encephalopathy and Treatment Modalities: A Review Article.
ammonia
antioxidant
encephalopathy
lactulose
rifaximin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
21
07
2022
accepted:
14
08
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
Hepatic encephalopathy (HE) is a condition that is commonly seen in individuals suffering from liver cirrhosis. After excluding brain illness, HE is described as a range of neuropsychiatric disorders in individuals with liver impairment. It is characterized by personality changes, intellectual impairment, and a depressed level of consciousness. Toxins that are typically eliminated from the body by the liver build up in the blood and eventually reach the brain, causing HE. Many signs and symptoms of HE may often be treated if caught early and treated properly. It is important to remember that not everyone who is affected may experience every symptom mentioned below. Affected individuals should speak with their doctor and medical staff about their specific disease, associated symptoms, and general prognosis. Many people only have minor symptoms, known as minimal HE. The exact pathophysiology of HE is still being debated, with the primary theories focusing on neurotoxins, reduced neurotransmission caused by alterations in brain energy metabolism, systemic inflammatory response, and blood-brain barrier (BBB) disturbances in liver failure, as well as metabolic irregularities.
Identifiants
pubmed: 36134085
doi: 10.7759/cureus.28016
pmc: PMC9470972
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28016Informations de copyright
Copyright © 2022, Sharma et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Metab Brain Dis. 2001 Jun;16(1-2):55-65
pubmed: 11726089
Arch Biochem Biophys. 2013 Aug 15;536(2):189-96
pubmed: 23583306
Ann Pharmacother. 2012 Nov;46(11):1559-63
pubmed: 23092866
N Engl J Med. 1999 Aug 5;341(6):403-9
pubmed: 10432325
Clin Gastroenterol Hepatol. 2014 Aug;12(8):1390-7.e2
pubmed: 24365449
Oxid Med Cell Longev. 2022 Feb 21;2022:7628522
pubmed: 35464767
Arch Biochem Biophys. 2013 Aug 15;536(2):158-63
pubmed: 23567841
J Gastroenterol Hepatol. 2013 May;28(5):783-92
pubmed: 23425108
Hepatology. 2010 Mar;51(3):1062-9
pubmed: 19890967
J Hepatol. 2019 Jan;70(1):40-49
pubmed: 30201461
Physiol Rev. 2002 Jan;82(1):47-95
pubmed: 11773609
Adv Exp Med Biol. 1994;368:125-34
pubmed: 7741004
Cochrane Database Syst Rev. 2004;(2):CD003044
pubmed: 15106187
Gastroenterology. 1999 Sep;117(3):640-4
pubmed: 10464140
Gastroenterol Rep (Oxf). 2017 May;5(2):138-147
pubmed: 28533911
Hepatology. 2016 Sep;64(3):908-22
pubmed: 27081787
Prog Brain Res. 2001;132:255-65
pubmed: 11544994
J Hepatol. 2016 Dec;65(6):1120-1130
pubmed: 27520878
J Hepatol. 2014 Feb;60(2):275-81
pubmed: 24128414
Acta Med Indones. 2011 Jan;43(1):18-22
pubmed: 21339541
Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:11-26
pubmed: 26618922
Liver Transpl. 2009 Feb;15(2):184-92
pubmed: 19177446
J Hepatol. 2020 Dec;73(6):1526-1547
pubmed: 33097308